We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Diabetes & Endocrinology

Enhancing MODY Diagnosis: The Clinical Value of Type 1 Diabetes Genetic Risk Scoring in Routine Genetic Testing

MedXY Editorial Team•Aug 19, 2026•Diabetes & Endocrinology
type 1 diabetes遺伝学的検査Genetic Risk ScoreMODYpediatric diabetes

Highlight

  • The type 1 diabetes genetic risk score (T1DGRS) measured alongside MODY gene panel testing identifies probable T1D cases within individuals initially referred for suspected MODY.
  • Approximately 20% of insulin-treated individuals referred for MODY testing carry a genetic risk profile consistent with T1D rather than monogenic diabetes.
  • Age-specific T1DGRS thresholds, especially in children under 10 years, enable effective pregenetic testing triage, potentially reducing over 50% of unnecessary genetic tests.
  • The clinical utility of T1DGRS diminishes in adults but remains valuable as part of genomic diagnostics in routine clinical practice.

Study Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Evaluating Beta Cell Function in Preclinical Type 1 Diabetes Using CGM-Derived Disposition IndexA novel CGM-derived disposition index reliably estimates beta cell function in individuals with islet autoimmunity without insulin therapy, predicting glycemic deterioration one year later.Oct 14, 2026Impact of School Care Locations on Glycemic Control in Children with Type 1 Diabetes: Insights from a Japanese Multicenter StudyThis study explores how the choice of diabetes self-care location at school affects glycemic control in children with Type 1 diabetes, highlighting restroom use as a risk factor for poorer outcomes and emphasizing the need for supportive scOct 13, 2026CGM Versus OGTT in Early-Stage Type 1 Diabetes: Comparative Predictive Accuracy and Clinical ImplicationsThis review synthesizes evidence demonstrating that continuous glucose monitoring (CGM) metrics, particularly time above 140 mg/dL, predict progression to stage 3 type 1 diabetes with accuracy comparable to oral glucose tolerance test (OGTTOct 11, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Cardiology
Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Unraveling Maternal Protection Against Type 1 Diabetes: Genetic Risk and Intrauterine Influences
This study reveals that the reduced risk of type 1 diabetes in children born to mothers with the condition is not due to genetic differences but possibly to protective intrauterine exposures during early childhood.
Oct 7, 2026
Genetic Testing in Endometrial Cancer: Prevalence of Pathogenic Germline Variants and Implications for Clinical Practice in a Diverse Community CohortIn a large, diverse cohort of women with endometrial cancer, 11.9% harbored pathogenic germline variants, including Lynch syndrome and homologous recombination deficiency-related mutations. Testing at diagnosis identified most Lynch syndromOct 6, 2026
Low-Dose Interleukin-2 in Newly Diagnosed Type 1 Diabetes: Insights from the DIABIL-2 Phase 2b TrialThe DIABIL-2 trial evaluated low-dose IL-2 therapy for preserving β-cell function in new-onset type 1 diabetes. Despite marked Treg expansion and good safety, IL-2 did not significantly preserve insulin secretion compared to placebo.Oct 5, 2026